Status:
UNKNOWN
Treating Obese PCOS Patients With LSG vs. Met
Lead Sponsor:
Shanghai 10th People's Hospital
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or...
Eligibility Criteria
Inclusion
- female aged 18- 45;
- meet Rotterdam criteria;
- BMI ≥ 28 kg /m2.
Exclusion
- Women who are pregnant or have a pregnancy plan within six months;
- Women who are reluctant to undergo metabolic surgery;
- Congenital adrenocortical hyperplasia;
- Hyperprolactinemia;
- Hyperthyroidism or hypothyroidism;
- Abnormal liver function (≥ 3 times of the upper limit of normal range); abnormal · Rrenal function (GFR\<60ml/min/1.73m2);
- Adrenal or ovarian tumors secreting androgens;
- Used contraceptives, metformin, GLP-1RA, pioglitazone and contraceptives in the last 3 month.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04508634
Start Date
November 1 2020
End Date
September 30 2024
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Tenth People' Hospital
Shanghai, Shanghai Municipality, China, 200072